Brendan Wood, Michelle Sholzberg, Alun Ackery
Abstract
Open-access reader
Rivaroxaban, apixaban and dabigatran are now commonly used as alternatives to vitamin K antagonist therapy (e.g., warfarin) for patients with atrial fibrillation, and for the treatment and prevention of venous thromboembolism. Dabigatran is a direct thrombin inhibitor, whereas apixaban and
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Rivaroxaban, apixaban and dabigatran are now commonly used as alternatives to vitamin K antagonist therapy (e.g., warfarin) for patients with atrial fibrillation, and for the treatment and prevention of venous thromboembolism. Dabigatran is a direct thrombin inhibitor, whereas apixaban and
Key concepts: Apixaban, Dabigatran, Rivaroxaban, Medicine, Vitamin K antagonist, Atrial fibrillation, Warfarin, Direct thrombin inhibitor